Key result
Previous hemorrhage (P=0.00001), liver disease (P=0.03), and amiodarone (P=0.009) increased risk of VKA overcoagulation, whereas statin therapy was protective (P=0.008).
Why the study?
What are the risk factors for overcoagulation in patients treated with vitamin K antagonists?
Population
412 patients treated with vitamin K antagonists referred to a Department of Internal Medicine over a 6-month…
Design
Cohort
Authors
Loading...
May warrant enhanced INR monitoring in at-risk VKA patients; leaves open confirmation of statin protection in trials.
Cohort (n=412)
No
What are the risk factors for overcoagulation in patients treated with vitamin K antagonists?
In patients on vitamin K antagonists, amiodarone use, chronic liver disease, and prior hemorrhage are significant risk factors for overcoagulation, while statin therapy may be protective.
Marié et al. (2011) conducted a cohort in Vitamin K antagonist overcoagulation (n=412). Vitamin K antagonists was evaluated on VKA-related overcoagulation (INR > 6.0 or INR 4.0-6.0 complicated with bleeding). Previous hemorrhage (P=0.00001), liver disease (P=0.03), and amiodarone (P=0.009) increased risk of VKA overcoagulation, whereas statin therapy was protective (P=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: